Moertel Criticizes Janssen Over Levamisole Price, Delivers Final Report On Intergroup Adjuvant Trial
In Brief: Seffrin’s ACS Appointment Is Official; Liotta Selected As NIH; Strategic Plan Meetings
Other ASCO Plenary Papers: Long Awaited Chemotherapy Results
Congress Okays NIH Reauthorization, Allows NCI $472 Mil. More
Gallo Inquiry Complete; NCAB’s AIDS Committee Plans Q&A Session
NCAB Decides To End IGs, Review total Research Support, And Consider P01 Limitation
Trending Stories
- Is it time to re-assess the practice and practicality of screening colonoscopy?
Modeling data, ACS guideline support greater use of noninvasive tests to ease system strain, help save lives - The Directors: Two Gulf Coast cancer center directors on why NCI designation matters—and why they want it
Lucio Miele and Raghu Kalluri: Science and technology have changed what an aspiring cancer center must accomplish - From “default dead” to living the future of cancer care
As founding CEO of GitLab, I went “founder mode” on my osteosarcoma - Brian Wolpin celebrates FDA approval of daraxonrasib in pancreatic cancer as the future of the field
- FDA advisory committee votes in favor of Galleri approval, but calls for removal of “early” detection claims
Clinical benefit will not be considered for approval, FDA says - Trump weighs—and abandons—an executive order that would give OMB veto power over NIH grants
